ACI’s Hatch-Waxman and BPCIA Proficiency Series
October 7, 2021
Partner Steve Maebius will present on a panel titled, “Small and Large Molecule Drug Patents and Other Related IP Protections and Mechanisms,” on Thursday, October 7, 2021 during ACI’s upcoming virtual three-week program. The program will provide an in-depth review of the IP basics relative to small molecules and biologics, as well as the regulation and litigation fundamentals of the Hatch-Waxman and Biologics Price Competition and Innovation (BPCIA) Acts.
Steve and his fellow panelists will discuss patent protections for drugs and biologics as well as trademark, trade name, and trade dress protections. The topics to be discussed include:
- Patent process for drugs and biologics
- Strategies for protecting patents for drugs and biologics
- Applying for and achieving extensions of patent terms for time spent in the drug approval process
- Patent Term Extension (“PTE”) and Patent Term Adjustment (“PTA”)
- The 271(e)(1) “safe harbor” provision
- Differences between the patenting process for drugs and biologics
- Selecting a brand name for a proposed drug product
- Duties of USPTO and FDA in drug naming process
- PTO and FDA clearances necessary for trade name and trademark approval of a product
- Importance of trade dress
- Branding process for a product
For more information and to register please visit the program website.
Author(s)
Related Insights
June 4, 2025
Energy Current
Nuclear’s Comeback: What Renewables Professionals Should Know
The clean energy transition isn’t a zero-sum game – it’s a team effort. And one player is stepping back into the spotlight with renewed…
June 4, 2025
Foley Ignite
M&A Disputes Set to Rise in Latin America: How Savvy Investors Are Protecting Themselves
As deal activity shows signs of rebounding in 2025, investors are bracing for an increase in M&A-related disputes globally, and Latin…
June 4, 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About … The Recent Court Decisions Striking Down the IEEPA Tariffs
This year, U.S. trade policy has undergone a dramatic shift, driven by a series of presidential proclamations that have raised tariff rates sharply.